Martin Mueller‐Zsigmondy
Novartis (Switzerland)(CH)
Publications by Year
Research Areas
Drug Solubulity and Delivery Systems, Advanced Breast Cancer Therapies, Neuroendocrine Tumor Research Advances, HER2/EGFR in Cancer Research, Nanoparticle-Based Drug Delivery
Most-Cited Works
- → FIP/AAPS guidelines to dissolution/in vitro release testing of novel/special dosage forms(2003)366 cited
- → Ribociclib Bioavailability Is Not Affected by Gastric pH Changes or Food Intake: In Silico and Clinical Evaluations(2017)78 cited
- → A survey on IVIVC/IVIVR development in the pharmaceutical industry – Past experience and current perspectives(2017)64 cited
- → Establishing the Bioequivalence Safe Space for Immediate-Release Oral Dosage Forms using Physiologically Based Biopharmaceutics Modeling (PBBM): Case Studies(2021)59 cited
- → Setting accelerated dissolution test for PLGA microspheres containing peptide, investigation of critical parameters affecting drug release rate and mechanism(2016)58 cited
- → Physiologically Based Biopharmaceutics Modeling to Demonstrate Virtual Bioequivalence and Bioequivalence Safe-space for Ribociclib which has Permeation Rate-controlled Absorption(2021)51 cited
- → Physiologically Based Pharmacokinetic Modeling of Oral Absorption, pH, and Food Effect in Healthy Volunteers to Drive Alpelisib Formulation Selection(2020)21 cited
- → In vivo release of peptide-loaded PLGA microspheres assessed through deconvolution coupled with mechanistic approach(2017)16 cited
- → Stimuli to the Revision Process: The Case for Apex Vessels(2021)13 cited
- → Establishing the Safe Space via Physiologically Based Biopharmaceutics Modeling. Case Study: Fevipiprant/QAW039(2023)12 cited